These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

321 related articles for article (PubMed ID: 16288045)

  • 1. Uncoupling between epidermal growth factor receptor and downstream signals defines resistance to the antiproliferative effect of Gefitinib in bladder cancer cells.
    Kassouf W; Dinney CP; Brown G; McConkey DJ; Diehl AJ; Bar-Eli M; Adam L
    Cancer Res; 2005 Nov; 65(22):10524-35. PubMed ID: 16288045
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of the therapeutic potential of the epidermal growth factor receptor tyrosine kinase inhibitor gefitinib in preclinical models of bladder cancer.
    Dominguez-Escrig JL; Kelly JD; Neal DE; King SM; Davies BR
    Clin Cancer Res; 2004 Jul; 10(14):4874-84. PubMed ID: 15269164
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Molecular aspects of gefitinib antiproliferative and pro-apoptotic effects in PTEN-positive and PTEN-negative prostate cancer cell lines.
    Festuccia C; Muzi P; Millimaggi D; Biordi L; Gravina GL; Speca S; Angelucci A; Dolo V; Vicentini C; Bologna M
    Endocr Relat Cancer; 2005 Dec; 12(4):983-98. PubMed ID: 16322337
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Resistance to small molecule inhibitors of epidermal growth factor receptor in malignant gliomas.
    Li B; Chang CM; Yuan M; McKenna WG; Shu HK
    Cancer Res; 2003 Nov; 63(21):7443-50. PubMed ID: 14612544
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Gefitinib reverses TRAIL resistance in human bladder cancer cell lines via inhibition of AKT-mediated X-linked inhibitor of apoptosis protein expression.
    Shrader M; Pino MS; Lashinger L; Bar-Eli M; Adam L; Dinney CP; McConkey DJ
    Cancer Res; 2007 Feb; 67(4):1430-5. PubMed ID: 17308080
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phosphorylated insulin-like growth factor 1 receptor is implicated in resistance to the cytostatic effect of gefitinib in colorectal cancer cells.
    Yang L; Li J; Ran L; Pan F; Zhao X; Ding Z; Chen Y; Peng Q; Liang H
    J Gastrointest Surg; 2011 Jun; 15(6):942-57. PubMed ID: 21479670
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Activated Src and Ras induce gefitinib resistance by activation of signaling pathways downstream of epidermal growth factor receptor in human gallbladder adenocarcinoma cells.
    Qin B; Ariyama H; Baba E; Tanaka R; Kusaba H; Harada M; Nakano S
    Cancer Chemother Pharmacol; 2006 Nov; 58(5):577-84. PubMed ID: 16532343
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dual-agent molecular targeting of the epidermal growth factor receptor (EGFR): combining anti-EGFR antibody with tyrosine kinase inhibitor.
    Huang S; Armstrong EA; Benavente S; Chinnaiyan P; Harari PM
    Cancer Res; 2004 Aug; 64(15):5355-62. PubMed ID: 15289342
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The MEK/MAPK pathway is involved in the resistance of breast cancer cells to the EGFR tyrosine kinase inhibitor gefitinib.
    Normanno N; De Luca A; Maiello MR; Campiglio M; Napolitano M; Mancino M; Carotenuto A; Viglietto G; Menard S
    J Cell Physiol; 2006 May; 207(2):420-7. PubMed ID: 16419029
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Metformin and gefitinib cooperate to inhibit bladder cancer growth via both AMPK and EGFR pathways joining at Akt and Erk.
    Peng M; Huang Y; Tao T; Peng CY; Su Q; Xu W; Darko KO; Tao X; Yang X
    Sci Rep; 2016 Jun; 6():28611. PubMed ID: 27334428
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Transforming growth factor alpha expression drives constitutive epidermal growth factor receptor pathway activation and sensitivity to gefitinib (Iressa) in human pancreatic cancer cell lines.
    Pino MS; Shrader M; Baker CH; Cognetti F; Xiong HQ; Abbruzzese JL; McConkey DJ
    Cancer Res; 2006 Apr; 66(7):3802-12. PubMed ID: 16585207
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Gefitinib (IRESSA) sensitive lung cancer cell lines show phosphorylation of Akt without ligand stimulation.
    Noro R; Gemma A; Kosaihira S; Kokubo Y; Chen M; Seike M; Kataoka K; Matsuda K; Okano T; Minegishi Y; Yoshimura A; Kudoh S
    BMC Cancer; 2006 Dec; 6():277. PubMed ID: 17150102
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Gefitinib inhibits the growth and invasion of urothelial carcinoma cell lines in which Akt and MAPK activation is dependent on constitutive epidermal growth factor receptor activation.
    Nicolle G; Daher A; Maillé P; Vermey M; Loric S; Bakkar A; Wallerand H; Vordos D; Vacherot F; de Medina SG; Abbou CC; Van der Kwast T; Thiery JP; Radvanyi F; Chopin DK
    Clin Cancer Res; 2006 May; 12(9):2937-43. PubMed ID: 16675591
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combined targeting of epidermal growth factor receptor and MDM2 by gefitinib and antisense MDM2 cooperatively inhibit hormone-independent prostate cancer.
    Bianco R; Caputo R; Caputo R; Damiano V; De Placido S; Ficorella C; Agrawal S; Bianco AR; Ciardiello F; Tortora G
    Clin Cancer Res; 2004 Jul; 10(14):4858-64. PubMed ID: 15269162
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combined epidermal growth factor receptor targeting with the tyrosine kinase inhibitor gefitinib (ZD1839) and the monoclonal antibody cetuximab (IMC-C225): superiority over single-agent receptor targeting.
    Matar P; Rojo F; Cassia R; Moreno-Bueno G; Di Cosimo S; Tabernero J; Guzmán M; Rodriguez S; Arribas J; Palacios J; Baselga J
    Clin Cancer Res; 2004 Oct; 10(19):6487-501. PubMed ID: 15475436
    [TBL] [Abstract][Full Text] [Related]  

  • 16. EGFR inhibition evokes innate drug resistance in lung cancer cells by preventing Akt activity and thus inactivating Ets-1 function.
    Phuchareon J; McCormick F; Eisele DW; Tetsu O
    Proc Natl Acad Sci U S A; 2015 Jul; 112(29):E3855-63. PubMed ID: 26150526
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Molecular mechanisms underlying effects of epidermal growth factor receptor inhibition on invasion, proliferation, and angiogenesis in experimental glioma.
    Guillamo JS; de Boüard S; Valable S; Marteau L; Leuraud P; Marie Y; Poupon MF; Parienti JJ; Raymond E; Peschanski M
    Clin Cancer Res; 2009 Jun; 15(11):3697-704. PubMed ID: 19435839
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Response to epidermal growth factor receptor inhibitors in non-small cell lung cancer cells: limited antiproliferative effects and absence of apoptosis associated with persistent activity of extracellular signal-regulated kinase or Akt kinase pathways.
    Janmaat ML; Kruyt FA; Rodriguez JA; Giaccone G
    Clin Cancer Res; 2003 Jun; 9(6):2316-26. PubMed ID: 12796401
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Receptor heterodimerization: a new mechanism for platelet-derived growth factor induced resistance to anti-epidermal growth factor receptor therapy for bladder cancer.
    Black PC; Brown GA; Dinney CP; Kassouf W; Inamoto T; Arora A; Gallagher D; Munsell MF; Bar-Eli M; McConkey DJ; Adam L
    J Urol; 2011 Feb; 185(2):693-700. PubMed ID: 21168861
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Suppression of epidermal growth factor receptor, mitogen-activated protein kinase, and Pak1 pathways and invasiveness of human cutaneous squamous cancer cells by the tyrosine kinase inhibitor ZD1839 (Iressa).
    Barnes CJ; Bagheri-Yarmand R; Mandal M; Yang Z; Clayman GL; Hong WK; Kumar R
    Mol Cancer Ther; 2003 Apr; 2(4):345-51. PubMed ID: 12700278
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.